We dedicate every day to supporting our mission: Improving patients’ quality of life by delivering personal insights at the genomic level of disease.

SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology and inflammatory diseases. The company is headquartered in Rotterdam (the Netherlands) and complemented with a state-of-the-art, CLIA-certified, CAP-accredited laboratory facilities in San Diego (CA, USA).

SkylineDx maintains R&D partnerships with leading health care providers and academic institutions around the world. The entrepreneurial approach of the thought leaders, combined with the scientific expertise of the SkylineDx team and global partners, positions them to solve diagnostic challenges and deliver on the promise of personalized healthcare. SkylineDx seeks to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, thereby improving patient outcomes. All R&D activities are captured in dedicated R&D Programs.

Merlin Test is a product originated from Falcon R&D Program in Dermatology (www.falconprogram.com). For physician and patient access to Merlin Test, SkylineDx collaborates with European partner and distributor Biocartis. Biocartis executes the customer facing role and their dedicated in-field teams will be your point of contact for any inquiries related to Merlin Test.

SkylineDx R&D Programs

Under the wings of the Falcon R&D Program, we have several active study initiatives in collaboration with an international medical field to identify solutions that address unmet needs. Aside from Merlin, the program harbors initiatives focused on prognostic utilities in melanoma (Peregrine and Kestrel) and Squamous Cell Carcinoma (Alopex), all committed to optimize the clinical pathway of patients.

Panthera R&D Program in Hematology is currently working on initiatives for multiple myeloma, plasma cell leukemia and acute myeloid leukemia. SKY92 is a product originated from this program and is commercially available in both EU and US for multiple myeloma. This test measures the expression levels of myeloma-specific tumor cells and is able to determine if a patient is at high-risk for early relapse and in need of intensified treatment strategies.

With Delphia R&D Program in Infectious and Inflammatory Disease, we are currently collaborating with renowned institutions in London and San Diego to develop a rapid, near-patient test to early diagnosis of Kawasaki disease. Kawasaki disease affects children and results in life-long cardio-vascular complications when treatment does not start in time. This test is not yet commercially available.